Drug intelligence / Profile preview

P59

Development stage: Preclinical
Administration: Intravenous

Overview

P59 is a C5a receptor 2 (C5aR2)-specific agonist being investigated for its therapeutic potential in diabetic kidney disease (DKD). It functions by activating c-FOS nuclear translocation, which in turn upregulates phosphatidylserine synthase (PSS) expression. This process promotes the interaction between PSS and mitochondrial fusion protein 2 (MFN2), thereby facilitating mitochondria-associated ER membrane (MAM) formation and phosphatidylserine (PS) biosynthesis. These actions lead to improved mitochondrial and endoplasmic reticulum (ER) function, ultimately offering protective effects in DKD.

Targets

C5AR2 (Complement component 5a receptor 2)

Beyond the preview

Go deeper on P59.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P59.

Explore the full profile